Skip to main content

Ikena Oncology Inc

For the period ended Mar 31, 2024. Filed May 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

IMA$3.97-3.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

March 31,2024December 31,2023
Assets
Current assets:
Cash and cash equivalents$52,852$119,894
Marketable securities104,49755,571
Prepaid expenses and other current assets3,8173,197
Total current assets161,166178,662
Property and equipment, net8642,335
Right-of-use asset5,2415,686
Deposits and other assets5,5115,409
Total assets$172,782$192,092
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$1,909$2,066
Accrued expenses and other current liabilities4,8178,581
Operating lease liability3,4433,558
Total current liabilities10,16914,205
Long-term portion of operating lease liability6,3027,180
Other long-term liabilities964950
Total liabilities17,43522,335
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; No shares issued and outstanding as of March 31, 2024 or December 31, 2023——
Common stock, $0.001 par value, 150,000,000 shares authorized and 48,258,111 shares issued and outstanding at March 31, 2024 and December 31, 20234848
Additional paid-in capital454,143452,142
Accumulated other comprehensive loss(313)(48)
Accumulated deficit(298,531)(282,385)
Total stockholders’ equity155,347169,757
Total liabilities and stockholders’ equity$172,782$192,092
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.